Clinical trials: Metastases to Bone
Breast Cancer With Metastatic Bone Disease
Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid
The aim of this prospective, randomized, open-label, multicentric clinical study is to assess the effícacy and tolerability of zoledronic acid 4 mg IV infused over 15 minutes every 4 weeks for a total of 6 infusions, in…
- Trial name
- NCT00172029
- Testing
- Zoledronic acid
- Where
- 7 sites in Turkey (Türkiye)
- Volunteers
- 116 people
- Sponsor
- Novartis
Cancer Related Pain
NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers
This is a multi-centre, long term, double blind, clinical protocol for NanaBis™ as a monotherapy treatment in participants 18-75 years of age with cancer related pain.
- Trial name
- NCT04808531
- Testing
- NanaBis™, Oxycodone CR, Oxycodone IR
- Volunteers
- 360 people
- Sponsor
- Medlab Clinical
Treatment of Bone Metastases
Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma
Zoledronic acid is a medication that slows the breakdown of bone. This study will assess the efficacy and safety of zoledronic acid in Chinese patients with multiple myeloma or other solid tumors with bone metastases.
- Trial name
- NCT00219258
- Testing
- Zoledronic acid
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Novartis
Prostatic Neoplasms
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
The primary objective in this study is to evaluate bone scan response at Week 24 based on the quantified technetium-99 bone scan lesion area (BSLA).
- Trial name
- NCT02034552
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Abiraterone acetate, Prednisone
- Where
- 19 sites in United States
- Volunteers
- 68 people
- Sponsor
- Bayer
Prostatic Neoplasms, Metastases, Neoplasm
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
The primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in men with prostate cancer
- Trial name
- NCT00055471
- Testing
- ZD4054 10 mg, ZD4054 15 mg, ZD4054 22.5 mg
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Bone Pain, Metastatic Bone Tumor
Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain
This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx in patients with painful bone metastases.
- Conditions
- Bone Pain, Metastatic Bone Tumor, Bone Metastases in Subjects With Advanced Cancer
- Trial name
- SOLACE (NCT07197645)
- Testing
- 153Sm-DOTMP
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Pain; Bone Neoplasms; Neoplasm Metastasis
A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer
This study will assess the short term efficacy of ibandronate (6 mg intravenous [IV]) in participants with breast cancer and malignant bone disease, with moderate to severe pain.
- Trial name
- NCT02553707
- Testing
- Ibandronate
- Where
- 15 sites in Hungary
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases
The purpose of the study was to determine the safety and test the efficacy of the combination of radium-223 dichloride and pembrolizumab in patients with stage IV non-small cell lung cancer (NSCLC) with bone metastases who either…
- Trial name
- NCT03996473
- Testing
- Radium-223 dichloride (Xofigo, BAY 88-8223), Pembrolizumab
- Where
- 6 sites in United States, Belgium and 2 more
- Volunteers
- 8 people
- Sponsor
- Bayer
Bone Metastases
First-In Man (FIM) Study MR-Linac
Investigational device is the Magnetic resonance imager linear accelerator. Five (5) patients with bone metastases will be treated with palliative intention in this study.
- Trial name
- FIM MR-Linac (NCT03284619)
- Testing
- Magnetic resonance imager linear accelerator
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Nucletron Operations BV
Solid Tumours, Bone Metastasis
Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw
Osteonecrosis of the Jaw (ONJ) is an adverse effect of antiresorptive therapy that is well-recognized in patients with advanced cancer.
- Trial name
- NCT01998607
- Testing
- Physician Survey
- Volunteers
- 420 people
- Sponsor
- Amgen
Prostate Cancer
A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)
The purpose of this study is to investigate the effects of MK0822 in prolonging the time to first bone metastasis in men with castration-resistant prostate cancer.
- Trial name
- NCT00691899
- Testing
- odanacatib
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases
This is a single-center, open-label, dose-escalating study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of single and multiple subcutaneous injection TK006 in patients with breast…
- Trial name
- NCT03239756
- Testing
- TK006
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jiangsu T-Mab Biopharma Co.,Ltd
Advanced Solid Tumors With Bone Only Metastasis
A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed
Bone metastasis is a common disease of advanced tumors. It refers to the metastasis of malignant tumors originating in a certain organ to the bones through the blood circulation or lymphatic system.
- Trial name
- NCT06416358
- Testing
- ALMB-0168
- Volunteers
- 144 people
- Sponsor
- AlaMab Therapeutics (Shanghai) Inc.
Bone Cancer, Bone Metastases
Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System
The goal of this prospective, non-randomized, single-arm, phase 2 study is to evaluate the safety and effectiveness of this treatment using this ExAblate conformal system in the treatment of pain resulting from metastatic bone…
- Conditions
- Bone Cancer, Bone Metastases, Pain
- Trial name
- NCT01085565
- Testing
- ExAblate 2100
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- InSightec
Metastatic Malignant Neoplasm
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors.
- Trial name
- NCT05958199
- Testing
- NPX267
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- NextPoint Therapeutics, Inc.
Pain, Neoplasm Metastasis
Safety and Efficacy of Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
This study will evaluate the safety and efficacy of cryoablation therapy combined with radiation therapy for the relief of pain associated with metastatic bone tumors.
- Trial name
- NCT01461252
- Testing
- Cryoablation, Radiation
- Sponsor
- Boston Scientific Corporation
Breast Cancer, Hypercalcemia of Malignancy
Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone.
- Conditions
- Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer, Pain
- Trial name
- NCT00060138
- Testing
- monoclonal antibody CAL, zoledronic acid
- Where
- United States
- Sponsor
- Chugai Pharmaceutical
Hyperparathyroidism, Secondary
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
This study is designed to assess the efficacy and safety of etelcalcetide (AMG 416) compared with placebo in the treatment of SHPT in CKD patients receiving hemodialysis.
- Trial name
- NCT01788046
- Testing
- Etelcalcetide
- Where
- 106 sites in United States, Australia and 13 more
- Volunteers
- 515 people
- Sponsor
- Amgen
Pain, Neoplasm Metastasis
Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases
This study will evaluate the safety and efficacy of cryoablation therapy for relief of pain associated with metastatic bone tumors.
- Trial name
- NCT01461265
- Testing
- Cryoablation
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 29 people
- Sponsor
- Boston Scientific Corporation
Pain
Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer
This study will evaluate the efficacy and safety of 4 mg zoledronic acid administered intravenously every 3-4 weeks in the treatment of bone metastases-related pain in patients with prostate cancer.
- Trial name
- TRAPEZE (NCT00375648)
- Testing
- Zoledronic acid
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals